BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 9743539)

  • 1. High frequency of skin-homing melanocyte-specific cytotoxic T lymphocytes in autoimmune vitiligo.
    Ogg GS; Rod Dunbar P; Romero P; Chen JL; Cerundolo V
    J Exp Med; 1998 Sep; 188(6):1203-8. PubMed ID: 9743539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytotoxic T lymphocyte reactivity to gp100, MelanA/MART-1, and tyrosinase, in HLA-A2-positive vitiligo patients.
    Mandelcorn-Monson RL; Shear NH; Yau E; Sambhara S; Barber BH; Spaner D; DeBenedette MA
    J Invest Dermatol; 2003 Sep; 121(3):550-6. PubMed ID: 12925214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HLA-A2 restricted, melanocyte-specific CD8(+) T lymphocytes detected in vitiligo patients are related to disease activity and are predominantly directed against MelanA/MART1.
    Lang KS; Caroli CC; Muhm A; Wernet D; Moris A; Schittek B; Knauss-Scherwitz E; Stevanovic S; Rammensee HG; Garbe C
    J Invest Dermatol; 2001 Jun; 116(6):891-7. PubMed ID: 11407977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Specific cytotoxic T lymphocyte responses against Melan-A/MART1, tyrosinase and gp100 in vitiligo by the use of major histocompatibility complex/peptide tetramers: the role of cellular immunity in the etiopathogenesis of vitiligo.
    Palermo B; Campanelli R; Garbelli S; Mantovani S; Lantelme E; Brazzelli V; Ardigó M; Borroni G; Martinetti M; Badulli C; Necker A; Giachino C
    J Invest Dermatol; 2001 Aug; 117(2):326-32. PubMed ID: 11511311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular and functional bases of self-antigen recognition in long-term persistent melanocyte-specific CD8+ T cells in one vitiligo patient.
    Mantovani S; Garbelli S; Palermo B; Campanelli R; Brazzelli V; Borroni G; Martinetti M; Benvenuto F; Merlini G; della Cuna GR; Rivoltini L; Giachino C
    J Invest Dermatol; 2003 Aug; 121(2):308-14. PubMed ID: 12880423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An expanded peripheral T cell population to a cytotoxic T lymphocyte (CTL)-defined, melanocyte-specific antigen in metastatic melanoma patients impacts on generation of peptide-specific CTLs but does not overcome tumor escape from immune surveillance in metastatic lesions.
    Anichini A; Molla A; Mortarini R; Tragni G; Bersani I; Di Nicola M; Gianni AM; Pilotti S; Dunbar R; Cerundolo V; Parmiani G
    J Exp Med; 1999 Sep; 190(5):651-67. PubMed ID: 10477550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytotoxic T lymphocyte responses against melanocytes and melanoma.
    Chang GY; Kohrt HE; Stuge TB; Schwartz EJ; Weber JS; Lee PP
    J Transl Med; 2011 Jul; 9():122. PubMed ID: 21794122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Melanocyte-specific, cytotoxic T cell responses in vitiligo: the effective variant of melanoma immunity?
    Garbelli S; Mantovani S; Palermo B; Giachino C
    Pigment Cell Res; 2005 Aug; 18(4):234-42. PubMed ID: 16029417
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T cell receptor (TCR) structure of autologous melanoma-reactive cytotoxic T lymphocyte (CTL) clones: tumor-infiltrating lymphocytes overexpress in vivo the TCR beta chain sequence used by an HLA-A2-restricted and melanocyte-lineage-specific CTL clone.
    Sensi M; Salvi S; Castelli C; Maccalli C; Mazzocchi A; Mortarini R; Nicolini G; Herlyn M; Parmiani G; Anichini A
    J Exp Med; 1993 Oct; 178(4):1231-46. PubMed ID: 8376931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Qualitative difference between the cytotoxic T lymphocyte responses to melanocyte antigens in melanoma and vitiligo.
    Palermo B; Garbelli S; Mantovani S; Scoccia E; Da Prada GA; Bernabei P; Avanzini MA; Brazzelli V; Borroni G; Giachino C
    Eur J Immunol; 2005 Nov; 35(11):3153-62. PubMed ID: 16224813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients.
    van den Boorn JG; Konijnenberg D; Dellemijn TA; van der Veen JP; Bos JD; Melief CJ; Vyth-Dreese FA; Luiten RM
    J Invest Dermatol; 2009 Sep; 129(9):2220-32. PubMed ID: 19242513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Global activation of CD8+ cytotoxic T lymphocytes correlates with an impairment in regulatory T cells in patients with generalized vitiligo.
    Lili Y; Yi W; Ji Y; Yue S; Weimin S; Ming L
    PLoS One; 2012; 7(5):e37513. PubMed ID: 22649532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anatomically distinct fibroblast subsets determine skin autoimmune patterns.
    Xu Z; Chen D; Hu Y; Jiang K; Huang H; Du Y; Wu W; Wang J; Sui J; Wang W; Zhang L; Li S; Li C; Yang Y; Chang J; Chen T
    Nature; 2022 Jan; 601(7891):118-124. PubMed ID: 34912121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of t cell-mediated vitiligo.
    Yee C; Thompson JA; Roche P; Byrd DR; Lee PP; Piepkorn M; Kenyon K; Davis MM; Riddell SR; Greenberg PD
    J Exp Med; 2000 Dec; 192(11):1637-44. PubMed ID: 11104805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunopolarization of CD4+ and CD8+ T cells to Type-1-like is associated with melanocyte loss in human vitiligo.
    Wańkowicz-Kalińska A; van den Wijngaard RM; Tigges BJ; Westerhof W; Ogg GS; Cerundolo V; Storkus WJ; Das PK
    Lab Invest; 2003 May; 83(5):683-95. PubMed ID: 12746478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generation of tumor-specific CTLs from melanoma patients by using peripheral blood stimulated with allogeneic melanoma tumor cell lines. Fine specificity and MART-1 melanoma antigen recognition.
    Stevens EJ; Jacknin L; Robbins PF; Kawakami Y; el Gamil M; Rosenberg SA; Yannelli JR
    J Immunol; 1995 Jan; 154(2):762-71. PubMed ID: 7814882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autoimmune vitiligo does not require the ongoing priming of naive CD8 T cells for disease progression or associated protection against melanoma.
    Byrne KT; Zhang P; Steinberg SM; Turk MJ
    J Immunol; 2014 Feb; 192(4):1433-9. PubMed ID: 24403535
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytotoxic T cells directed to tumor antigens not expressed on normal melanocytes dominate HLA-A2.1-restricted immune repertoire to melanoma.
    Anichini A; Mortarini R; Maccalli C; Squarcina P; Fleischhauer K; Mascheroni L; Parmiani G
    J Immunol; 1996 Jan; 156(1):208-17. PubMed ID: 8598464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Melanoma cells and normal melanocytes share antigens recognized by HLA-A2-restricted cytotoxic T cell clones from melanoma patients.
    Anichini A; Maccalli C; Mortarini R; Salvi S; Mazzocchi A; Squarcina P; Herlyn M; Parmiani G
    J Exp Med; 1993 Apr; 177(4):989-98. PubMed ID: 8459226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of fluorogenic histocompatibility leukocyte antigen-A*0201/HPV 16 E7 peptide complexes to isolate rare human cytotoxic T-lymphocyte-recognizing endogenous human papillomavirus antigens.
    Youde SJ; Dunbar PR; Evans EM; Fiander AN; Borysiewicz LK; Cerundolo V; Man S
    Cancer Res; 2000 Jan; 60(2):365-71. PubMed ID: 10667589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.